NCT06304168

Validation of DNA Methylation Markers for Universal and Site-specific Guided Cancer Detection, VANGUARD Study

Validation of DNA Methylation Markers for the Universal and Site-Specific Guided Cancer Detection (the VANGUARD Study)

• Status: Recruiting
• Phase: —
• Study type: Observational
• Enrollment: 6,150 (estimated)
• Sponsor: Mayo Clinic · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Accepted

Summary

This study explores the potential value of a new blood test approach for early detection of cancer.

Detailed description

PRIMARY OBJECTIVES: I. Validate candidate universal and site-specific MDMs in DNA extracted from formalin-fixed paraffin embedded primary tumor and control specimens. II. Test MDM-based models for detection of the top 16 most lethal human cancers using a non-invasive biological medium, specifically blood. III. Assess feasibility for detection of cancers using urine samples to assay MDMs, RNA or protein in cell free or extra-cellular vesicles; patients may be the same or unique individuals from Aim 1 and 2. OUTLINE: This is an observational study. Patients undergo blood, urine, and/or residual tissue sample collection and have their medical records reviewed on study.

Conditions

• Hematopoietic and Lymphatic System Neoplasm
• Malignant Solid Neoplasm

Interventions

Type	Name	Description
OTHER	Non-Interventional Study	Non-interventional study

Timeline

• Start date: 2019-05-13
• Primary completion: 2028-05-15
• Completion: 2028-05-15
• First posted: 2024-03-12
• Last updated: 2026-03-03

Locations

1 site across 1 country: United States